Actively Recruiting
Negative Serology by Immunoenzymatic Test (EIA) in HIV-infected Children Treated Early With Antiretroviral in the ANRS-Pediacam Study: Pathophysiological Mechanisms
Led by ANRS, Emerging Infectious Diseases · Updated on 2025-01-30
451
Participants Needed
3
Research Sites
69 weeks
Total Duration
On this page
Sponsors
A
ANRS, Emerging Infectious Diseases
Lead Sponsor
C
Centre Pasteur du Cameroun
Collaborating Sponsor
AI-Summary
What this Trial Is About
The objective of the study is to identify the pathophysiological mechanisms responsible for the induction and maintenance of negative serologies by EIA tests in HIV-infected children treated early with HAART in the ANRS 12225-Pediacam III cohort in Cameroon The hypothesis of better control of HIV infection through interactions between immunological, viral, and genetic factors was made to build the following objectives: * Immunological aspect: lack of humoral response or immune activation * Virological aspect: Reduced HIV reservoir size * Determine the HLA phenotype in the different groups of children included and the KIR genotypes.
CONDITIONS
Official Title
Negative Serology by Immunoenzymatic Test (EIA) in HIV-infected Children Treated Early With Antiretroviral in the ANRS-Pediacam Study: Pathophysiological Mechanisms
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Children included and followed in the ANRS 12225 study - Pediacam III
- Having plasma samples in the biobank during the specified periods
- Cases: Children with at least one negative HIV serology by ELISA, permanent or transient during follow-up
- Controls: HIV-infected children with positive serology and viral load less than 400 copies/ml
- Controls: HIV-infected children with positive serology and viral load 400 copies/ml or more
- Controls: HIV-uninfected children born to HIV-positive mothers
- Controls: HIV-uninfected children born to HIV-uninfected mothers
- Selection of cases and controls matched on gestational age (premature less than 37 weeks, term 37 weeks or more) and year of birth (2007-2008 and 2009-2010)
- All children still followed in the ANRS - Pediacam III cohort (for cross-sectional study)
- Written consent of one parent or guardian and assent of the child if aged 11 years or older with full disclosure of HIV status for infected children
You will not qualify if you...
- Refusal by a parent or guardian for the child's participation in the study
- No assent by the child if aged 11 years or older with full disclosure of HIV status for infected children
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Hôpital de Jour - Hôpital Laquintinie de Douala
Douala, Cameroon, 4035
Not Yet Recruiting
2
Unité Pédiatrique de Jour - Centre Mère et Enfant de la Fondation Chantal Biya
Yaoundé, Cameroon, 1274
Actively Recruiting
3
Service de Pédiatrie - Centre Hospitalier d'Essos
Yaoundé, Cameroon, 5777
Actively Recruiting
Research Team
M
Mathurin C Tejiokem, Doctor
CONTACT
A
Albert Faye, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here